Literature DB >> 8500266

Spontaneous recovery from the Guillain-Barré syndrome is associated with anti-idiotypic antibodies recognizing a cross-reactive idiotype on anti-neuroblastoma cell line antibodies.

I Lundkvist1, P A van Doorn, M Vermeulen, A Brand.   

Abstract

The presence of suppressive antibody activity in sera from patients spontaneously recovered from the Guillain-Barré syndrome was investigated by analyzing the ability of postrecovery serum to inhibit anti-neuroblastoma cell line antibody binding in sera from seven patients in the prerecovery phase or with a chronic form of the disease. All 12 recovered patients analyzed were found to have inhibitory IgG antibodies in their postrecovery sera, of which the F(ab')2 fragments mediated the inhibitory effect. The pattern of inhibition suggests that about half of the patients share cross-reactive idiotypes of high affinity. The efficiency of the inhibition mediated by anti-idiotypic antibodies in spontaneously recovered patients was twice as high as that mediated by anti-idiotypes present in therapeutical preparations of polyclonal immunoglobulins for intravenous use (IVIG). Affinity chromatography of IVIG and serum from a recovered Guillain-Barré syndrome patient on autoantibody-containing F(ab')2 fragments revealed, first, that inhibitory anti-idiotypic antibodies are specifically retained on autoantibodies and, second, that these antibodies constitute less than 1% of the total IgG antibody content.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8500266     DOI: 10.1006/clin.1993.1064

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  12 in total

Review 1.  Immunomodulation of autoimmune diseases by high-dose intravenous immunoglobulins.

Authors:  L Rauova; J Rovensky; Y Shoenfeld
Journal:  Springer Semin Immunopathol       Date:  2001-12

Review 2.  Toward molecular targeting with specific intravenous immunoglobulin preparation.

Authors:  Miri Blank; Israel Nur; Orgad Toub; Anabel Maor; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Intravenous immunoglobulin for treatment of pemphigus.

Authors:  Lehavit Akerman; Daniel Mimouni; Michael David
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 4.  Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Authors:  J W Terryberry; Y Shoenfeld; J B Peter
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

5.  Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; L Ashkenazi; Y Milner; M Frusic-Zlotkin; G J Anhalt; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

6.  Anti-beta-tubulin antibodies have no diagnostic value in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  I N van Schaik; M Vermeulen; P A van Doorn; A Brand
Journal:  J Neurol       Date:  1995-09       Impact factor: 4.849

Review 7.  In vitro effects of polyvalent immunoglobulin for intravenous use.

Authors:  I N van Schaik; M Vermeulen; A Brand
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

Review 9.  Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy.

Authors:  P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

10.  Structural basis for the recognition in an idiotype-anti-idiotype antibody complex related to celiac disease.

Authors:  Anna Vangone; Safwat Abdel-Azeim; Ivana Caputo; Daniele Sblattero; Roberto Di Niro; Luigi Cavallo; Romina Oliva
Journal:  PLoS One       Date:  2014-07-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.